DPx Launched as Provider of Pharmaceutical Services, Fine Chemicals, and Proprietary Technologies - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

DPx Launched as Provider of Pharmaceutical Services, Fine Chemicals, and Proprietary Technologies



DPx Holdings is a new CDMO for the pharmaceutical and related industries, formed from a $2.65 billion transaction between JLL Partners, a private equity firm, and Royal DSM, a life-sciences and materials sciences company. DPx is 51% owned by JLL Partners and 49% by Royal DSM.

Formerly known by its provisional name “NewCo,” DPx is the corporate parent of a group of business units that is comprised of three brands focused on pharmaceutical services, fine chemicals and products, and proprietary technologies. These units are the result of combining DSM Pharmaceutical Products (DPP), Patheon, and Banner Life Sciences.

Pharmaceutical services will operate under the Patheon brand name and include the CMO capabilities, pharmaceutical product development services, as well as biosolutions and biologics businesses of DPP. In addition, fine chemicals, or the ES/IM and API businesses, will operate under the brand name DSM Fine Chemicals, while proprietary products and technologies will operate under Banner Life Sciences.

DSM Fine Chemicals will also handle complicated APIs and finished dosage forms, and Banner Life Sciences will offer its own proprietary and nutraceutical products to the market.

DPx’s 2014 sales are expected to be about $2 billion (pro-forma). DPx has 24 locations across North America, Europe, Latin America, and Australia with more than 8000 employees.

Source: DPx Holdings

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality

Click here